Odyssey Health, Inc.
For the period ended Apr 30, 2025. Filed Jun 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Apr 30, 2025 · Filed Jun 13, 2025
ODYYStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| For the Nine Months Ended April 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net income (loss) | $(1,490,775) | $11,897,190 |
| Adjustments to reconcile net income (loss) to net cash flows used in operating activities: | ||
| Amortization | – | 1,538 |
| Stock-based compensation | 108,399 | 1,051,602 |
| Gain on sale of asset | – | (16,400,687) |
| Financing costs paid with issuance of common stock | – | 8,750 |
| Amortization of beneficial conversion feature, debt discount and closing costs | 43,464 | 284,665 |
| Allowance for research and development rebate due from Australian government | 22,625 | – |
| Change in fair value of investment in common stock | 432,054 | 1,700,909 |
| Changes in operating assets and liabilities: | ||
| (Increase) decrease in prepaid expenses and other current assets | (32,234) | 27,693 |
| Decrease in research and development rebate due from Australian government | – | 253,941 |
| Increase (decrease) in accounts payable | 201,581 | (175,416) |
| Increase in accrued wages | 268,357 | 84,825 |
| Increase in accrued interest | 147,336 | 113,415 |
| Net cash used in operating activities | (299,193) | (1,151,575) |
| Cash flows from investing activities: | ||
| Cash proceeds from sale of assets | – | 1,000,000 |
| Net cash provided by investing activities | – | 1,000,000 |
| Cash flows from financing activities: | ||
| Proceeds from notes payable | 300,000 | 400,000 |
| Principal payments made on notes payable | – | (274,896) |
| Proceeds from equity financing | – | 55,620 |
| Net cash provided by financing activities | 300,000 | 180,724 |
| Net increase in cash | 807 | 29,149 |
| Cash at beginning of period | 2,379 | 36,865 |
| Cash at end of period | $3,186 | $66,014 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $2,811 | $36,319 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Warrants issued in connection with debt financing | $13,343 | $28,448 |
| Common stock issued to settle notes payable and accrued interest | – | 993,872 |
| Increase in fees related to extension of LGH debt maturity date recorded as additional principal | – | 60,000 |
| Shares issued for exercised warrants | – | 3,536 |
| Shares returned | – | 100 |
| Deemed dividend for the reduction of exercise price of warrants | – | 63,455 |
| Accounts payable assumed by Oragenics, Inc. | – | 325,672 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.